|| Checking for direct PDF access through Ovid
The aim of the present report was to study the role of sparfloxacin in retreatment of pulmonary tuberculosis.Sixteen patients with sputum-smear-positive pulmonary tuberculosis were given sparfloxacin (200 mg daily), along with isoniazid and para-aminosalicylic acid plus additional drugs where indicated. They were followed up and assessed by sputum-smear microscopy and chest X-ray regularly for the entire duration of follow up, which ranged from 15 to 18 months.Twelve patients completed treatment and achieved a satisfactory response in the form of persistent sputum negativity and radiologically quiescent disease. Two patients defaulted after 6 months and one patient discontinued medications because of severe gastrointestinal intolerance. One patient died before completion of the treatment as a result of the sequelae of the disease.Sparfloxacin can be used as a companion drug along with other drugs in retreatment of pulmonary tuberculosis. The advantages of this drug are a high safety profile, low cost of treatment and easy availability, which are important determinants, especially in developing countries.